Danone further invests in gut health and next-generation biotic research with the acquisition of The Akkermansia Company
Danone (OTC:DANOY) has announced the acquisition of The Akkermansia Company (TAC), a Belgian biotic specialist with nearly 20 years of expertise. TAC is known for its groundbreaking 2004 discovery of Akkermansia muciniphila MucT™, a biotic strain clinically proven to strengthen gut barriers, reduce inflammation, and combat metabolic disorders including obesity, diabetes, and cardiovascular disease.
This strategic acquisition aligns with Danone's Renew strategy, emphasizing scientific innovation and responding to growing consumer demand for health-focused products. The company, which generated €27.4 billion in sales in 2024, operates across three health-focused categories: Essential Dairy & Plant-Based products, Waters, and Specialized Nutrition, with products available in over 120 markets globally.
Danone (OTC:DANOY) ha annunciato l'acquisizione di The Akkermansia Company (TAC), uno specialista belga nel campo dei biotici con quasi 20 anni di esperienza. TAC è nota per la sua scoperta rivoluzionaria del 2004 del Akkermansia muciniphila MucT™, un ceppo biotico clinicamente dimostrato capace di rafforzare le barriere intestinali, ridurre l'infiammazione e contrastare disturbi metabolici come obesità, diabete e malattie cardiovascolari.
Questa acquisizione strategica si allinea con la strategia Renew di Danone, che punta sull'innovazione scientifica e risponde alla crescente domanda dei consumatori di prodotti orientati alla salute. L'azienda, che ha generato 27,4 miliardi di euro di fatturato nel 2024, opera in tre categorie focalizzate sulla salute: prodotti lattiero-caseari essenziali e a base vegetale, acque e nutrizione specializzata, con prodotti disponibili in oltre 120 mercati a livello globale.
Danone (OTC:DANOY) ha anunciado la adquisición de The Akkermansia Company (TAC), un especialista belga en bioticos con casi 20 años de experiencia. TAC es reconocida por su descubrimiento innovador en 2004 del Akkermansia muciniphila MucT™, una cepa biotica clínicamente probada para fortalecer las barreras intestinales, reducir la inflamación y combatir trastornos metabólicos como la obesidad, diabetes y enfermedades cardiovasculares.
Esta adquisición estratégica se alinea con la estrategia Renew de Danone, que enfatiza la innovación científica y responde a la creciente demanda de los consumidores por productos enfocados en la salud. La compañía, que generó 27.4 mil millones de euros en ventas en 2024, opera en tres categorías centradas en la salud: productos lácteos esenciales y a base de plantas, aguas y nutrición especializada, con productos disponibles en más de 120 mercados a nivel mundial.
다논 (OTC:DANOY)은 거의 20년의 전문 지식을 가진 벨기에의 바이오틱 전문 기업인 The Akkermansia Company (TAC)를 인수했다고 발표했습니다. TAC는 2004년에 획기적으로 발견한 Akkermansia muciniphila MucT™라는 바이오틱 균주로 잘 알려져 있으며, 이 균주는 장벽을 강화하고 염증을 줄이며 비만, 당뇨병, 심혈관 질환을 포함한 대사 장애를 치료하는 임상적 효능이 입증되었습니다.
이번 전략적 인수는 다논의 Renew 전략과 부합하며, 과학적 혁신을 강조하고 건강 중심 제품에 대한 소비자 수요 증가에 대응합니다. 2024년에 274억 유로의 매출을 기록한 이 회사는 필수 유제품 및 식물성 제품, 생수, 전문 영양 등 세 가지 건강 중심 카테고리에서 사업을 운영하며 전 세계 120개 이상의 시장에 제품을 공급하고 있습니다.
Danone (OTC:DANOY) a annoncé l'acquisition de The Akkermansia Company (TAC), un spécialiste belge des biotiques avec près de 20 ans d'expertise. TAC est reconnue pour sa découverte révolutionnaire en 2004 de Akkermansia muciniphila MucT™, une souche biotique cliniquement prouvée pour renforcer les barrières intestinales, réduire l'inflammation et lutter contre les troubles métaboliques tels que l'obésité, le diabète et les maladies cardiovasculaires.
Cette acquisition stratégique s'inscrit dans la stratégie Renew de Danone, mettant l'accent sur l'innovation scientifique et répondant à la demande croissante des consommateurs pour des produits axés sur la santé. L'entreprise, qui a généré 27,4 milliards d'euros de chiffre d'affaires en 2024, opère dans trois catégories axées sur la santé : produits laitiers essentiels et à base de plantes, eaux et nutrition spécialisée, avec des produits disponibles dans plus de 120 marchés à travers le monde.
Danone (OTC:DANOY) hat die Übernahme von The Akkermansia Company (TAC) bekannt gegeben, einem belgischen Biotik-Spezialisten mit fast 20 Jahren Erfahrung. TAC ist bekannt für die bahnbrechende Entdeckung von Akkermansia muciniphila MucT™ im Jahr 2004, einem biotischen Stamm, der klinisch nachweislich die Darmbarrieren stärkt, Entzündungen reduziert und Stoffwechselerkrankungen wie Fettleibigkeit, Diabetes und Herz-Kreislauf-Erkrankungen bekämpft.
Diese strategische Übernahme steht im Einklang mit Danones Renew-Strategie, die wissenschaftliche Innovation betont und auf die wachsende Nachfrage der Verbraucher nach gesundheitsorientierten Produkten reagiert. Das Unternehmen, das im Jahr 2024 einen Umsatz von 27,4 Milliarden Euro erzielte, ist in drei gesundheitsfokussierten Kategorien tätig: Essential Dairy & Plant-Based Produkte, Wasser und Spezialernährung, mit Produkten in über 120 Märkten weltweit.
- Strategic expansion into gut health research and next-generation biotics
- Acquisition adds clinically proven biotic strain with multiple health benefits
- Aligns with growing consumer demand for health-focused products
- Strengthens Danone's scientific innovation capabilities
- Financial terms of the acquisition not disclosed
- Integration costs and timeline uncertainties
- Potential regulatory and commercialization challenges for new biotic products
Press release – Paris, June 25, 2025, at 18:00 CEST
Danone further invests in gut health and next-generation biotic research with the acquisition of The Akkermansia Company
Danone today announces the acquisition of The Akkermansia Company (TAC), a Belgian company with nearly 20 years of history and science, specializing in biotics.
In 2004, using state-of-the-art technology, scientists at TAC discovered and developed a biotic strain, Akkermansia muciniphila MucT™. They clinically demonstrated its power to reinforce the gut barrier, reduce inflammation, and counteract metabolic disorders such as obesity, diabetes, and cardiovascular disease.
Expanding deeper into gut health is a key facet of Danone’s Renew strategy, as it doubles down on science and innovation, and as consumer interest in healthy products continues to rise.
About Danone (www.danone.com)
Danone is a leading global food and beverage company operating in three health-focused, fast-growing and on-trend Categories: Essential Dairy & Plant-Based products, Waters and Specialized Nutrition. With a long-standing mission of bringing health through food to as many people as possible, Danone aims to inspire healthier and more sustainable eating and drinking practices while committing to achieve measurable nutritional, social, societal and environment impact. Danone has defined its Renew strategy to restore growth, competitiveness, and value creation for the long-term. With over 90,000 employees, and products sold in over 120 markets, Danone generated
o o O o o
FORWARD-LOOKING STATEMENTS
This press release contains certain forward-looking statements concerning Danone that are subject to risks and uncertainties. Generally, you can identify these forward-looking statements by forward-looking words, such as “estimate”, “expect”, “anticipate”, “project”, “plan”, “intend”, “objective”, “believe”, “forecast”, “guidance”, “foresee”, “likely”, “may”, “should”, “goal”, “target”, “might”, “will”, “could”, “predict”, “continue”, “convinced” and “confident,” the negative or plural of these words and other comparable terminology or by using future dates. Forward-looking statements in this press release include but are not limited to predictions of future activities, operations, direction, performance and results of Danone. These forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. For a detailed description of risks and uncertainties, please refer to the “Risk Factor” section of Danone’s Universal Registration Document (the current version of which is available at www.danone.com).
Subject to regulatory requirements, Danone does not undertake to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell or a solicitation of an offer to buy Danone securities.
Attachment
FAQ
What company did Danone (DANOY) acquire in June 2025?
What is the significance of Akkermansia muciniphila MucT™?
How does this acquisition align with Danone's strategy?
What were Danone's sales figures for 2024?
What are Danone's main business categories?
